Johnson & Johnson's Q4 Earnings Show Much Work Remains For Management

By Stephen Simpson:In the realm of healthcare stocks too cheap to ignore, there are a lot of different stories to suit individual investor tastes.

Ockham Research submits: Johnson & Johnson (JNJ) is one of those stocks that rarely produces a lot of excitement for investors; what you see is what you get.

By Stephen Simpson:Over the past year or so, investors have come back to the med-tech space and pushed valuations back up to levels closer to historical norms. Although that means a lot of easy money is gone, many of these companies still hold worthwhile potential as long-term holdings. Among them, Stryker (SYK) may still be among the most interesting.

By Valuentum: Diversified medical and consumer products firm Johnson & Johnson (JNJ) reported solid fourth-quarter results Tuesday morning. Sales jumped 8% year-over-year to $17.6 billion, roughly in-line with consensus expectations. Earnings were slightly better than anticipated, growing 5.3% year-over-year to $1.19 per share-after adjusting for several special items.

By AnalytixInsight:Medtronic Inc. recently reported its preliminary financial results based on which CapitalCube provides a unique peer-based analysis of the company. Our analysis is based on the company's performance over the last twelve months (unless stated otherwise).

By Osman Gulseven: By: Ahmed Ishtiaq

ByNick Chiu:Johnson & Johnson (JNJ) is the world's largest and most diverse health-care company, which comprises three divisions: pharmaceutical, medical devices and diagnostics, and consumer.

By Valuentum: Johnson & Johnson (JNJ) reported mixed fourth-quarter results Tuesday. Though we weren't exactly enthralled by the firm's performance, we believe JNJ to be a key holding in the portfolio of our Dividend Growth Newsletter. Our fair value estimate for JNJ is unchanged at this time.